<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00840606</url>
  </required_header>
  <id_info>
    <org_study_id>R01-654</org_study_id>
    <nct_id>NCT00840606</nct_id>
  </id_info>
  <brief_title>Buspirone Hydrochloride 30mg Tablets, Fasting</brief_title>
  <official_title>A Relative Bioavailability Study of 30 mg Buspirone Hydrochloride Tablets Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the relative bioavailability (rate and extent of absorption) of 30 mg&#xD;
      Buspirone Hydrochloride Tablets by TEVA Pharmaceuticals Industries, Ltd. with that of 30 mg&#xD;
      BUSPAR® Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 30 mg&#xD;
      tablet) in healthy adult volunteers under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria for Evaluation: FDA Bioequivalence Criteria&#xD;
&#xD;
      Statistical Methods: FDA bioequivalence statistical methods&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">April 2002</completion_date>
  <primary_completion_date type="Actual">December 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax</measure>
    <time_frame>Blood samples collected over 24 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence based on AUC0-inf</measure>
    <time_frame>Blood samples collected over 24 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence based on AUC0-t</measure>
    <time_frame>Blood samples collected over 24 hour period</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BUSPAR® 30 mg Tablet</intervention_name>
    <description>1 x 30 mg, single-dose fasting</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buspirone Hydrochloride 30 mg Tablet</intervention_name>
    <description>1 x 30 mg, single-dose fasting</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Screening Demographics: All volunteers selected for this study will be healthy men or&#xD;
             women 18 years of age or older at the time of dosing. The volunteer's body mass index&#xD;
             (BMI) is less than or equal to 30.&#xD;
&#xD;
          -  Screening Procedures: Each volunteer will complete the screening process within 28&#xD;
             days prior to Period I dosing. Consent documents for both the screening evaluation and&#xD;
             HIV antibody determination will be reviewed, discussed, and signed by each potential&#xD;
             participant before full implementation of screening procedures.&#xD;
&#xD;
        Screening will include general observations, physical examination, demographics, medical&#xD;
        and medication history, an electrocardiogram, sitting blood pressure and heart rate,&#xD;
        respiratory rate and temperature. The physical examination will include, but may not be&#xD;
        limited to, an evaluation of the cardiovascular, gastrointestinal, respiratory, and central&#xD;
        nervous systems.&#xD;
&#xD;
          -  The screening clinical laboratory procedures will include:&#xD;
&#xD;
               -  Hematology: hematocrit, hemoglobin, RBC count, WBC count with differential,&#xD;
                  platelet count;&#xD;
&#xD;
               -  Clinical Chemistry: serum creatinine, BUN, glucose, AST(GOT), ALT(GPT), albumin,&#xD;
                  total bilirubin, total protein, and alkaline phosphatase.&#xD;
&#xD;
               -  HIV antibody and hepatitis B surface antigen screens;&#xD;
&#xD;
               -  Urinalysis: by dipstick; full microscopic examination if dipstick positive; and&#xD;
&#xD;
               -  Urine Drug Screen: ethyl alcohol, amphetamines, barbiturates, benzodiazepines,&#xD;
                  cannabinoids, cocaine metabolites, opiates, and phencyclidine;&#xD;
&#xD;
               -  Serum Pregnancy Screen (female volunteers only).&#xD;
&#xD;
          -  If female and:&#xD;
&#xD;
               -  of childbearing potential, is practicing an acceptable method of birth control&#xD;
                  for the duration of the study as judged by the investigator(s), such as condoms,&#xD;
                  foams, jellies, diaphragm, intrauterine device (IUD), or abstinence; or&#xD;
&#xD;
               -  is postmenopausal for at least 1 year; or&#xD;
&#xD;
               -  is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or&#xD;
                  hysterectomy).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Volunteers with a recent history of drug or alcohol addiction or abuse.&#xD;
&#xD;
          -  Volunteers with the presence of a clinically significant disorder involving the&#xD;
             cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic,&#xD;
             endocrine, or neurologic system(s) or psychiatric disease (as determined by the&#xD;
             clinical investigators).&#xD;
&#xD;
          -  Volunteers whose clinical laboratory test values are outside the accepted reference&#xD;
             range and when confirmed on re-examination are deemed to be clinically significant.&#xD;
&#xD;
          -  Volunteers demonstrating a positive hepatitis B surface antigen screen or a reactive&#xD;
             HIV antibody screen.&#xD;
&#xD;
          -  Volunteers demonstrating a positive drug abuse screen when screened for this study.&#xD;
&#xD;
          -  Female volunteers demonstrating a positive pregnancy screen.&#xD;
&#xD;
          -  Female volunteers who are currently breastfeeding.&#xD;
&#xD;
          -  Volunteers with a history of allergic response(s) to buspirone or related drugs.&#xD;
&#xD;
          -  Volunteers with a history of clinically significant allergies including drug&#xD;
             allergies.&#xD;
&#xD;
          -  Volunteers with a clinically significant illness during 4 weeks prior to Period I&#xD;
             dosing (as determined by the clinical investigators).&#xD;
&#xD;
          -  Volunteers who are currently using or report using tobacco products within 90 days&#xD;
             prior to Period I dosing.&#xD;
&#xD;
          -  Volunteers who have taken any drug known to induce or inhibit hepatic drug metabolism&#xD;
             in the 30 days prior to Period I dosing.&#xD;
&#xD;
          -  Volunteers who report donating greater than 150 mL of blood within 30 days prior to&#xD;
             Period I dosing. All subjects will be advised not to donate blood for four weeks after&#xD;
             completing the study.&#xD;
&#xD;
          -  Volunteers who have donated plasma (e.g. plasmapheresis) within 14 days prior to&#xD;
             Period I dosing. All subjects will be advised not to donate plasma for four weeks&#xD;
             after completing the study.&#xD;
&#xD;
          -  Volunteers who report receiving any investigational drug within 30 days prior to&#xD;
             Period I dosing.&#xD;
&#xD;
          -  Volunteers who report taking any prescription medication or nonprescription medication&#xD;
             in the 14 days or 7 days, respectively, prior to Period I dosing with the exception of&#xD;
             topical products without systemic absorption.&#xD;
&#xD;
          -  Volunteers who have been on an abnormal diet during the 28 days prior to Period I&#xD;
             dosing.&#xD;
&#xD;
          -  Volunteers who report an intolerance or direct venipuncture.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James D. Carlson, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRACS Institute, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRACS Institute, Ltd.</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 6, 2009</study_first_submitted>
  <study_first_submitted_qc>February 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2009</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buspirone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

